Citigroup maintains CRSP (CRISPR Therapeutics AG) at Buy Feb 2026

NodeGuardian · 2026-03-08T06:57:33+00:00

Citigroup reaffirmed a "Buy" rating for CRISPR Therapeutics, raising its price target from $77 to $80, indicating confidence in the company's progress and valuation. Investors should factor in this positive outlook with other market influences.

NodeGuardian

2026-03-08 06:57:33

Abstract generation in progress

Citigroup maintained its “Buy” rating for CRISPR Therapeutics AG (CRSP) on February 16, 2026, and increased its price target from $77 to $80. This action reflects the firm’s continued confidence in the company’s valuation and pipeline progress. While the increase is modest, it suggests a constructive view for investors, who should consider this alongside other research and company catalysts.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes